Overview
- The FDA approved a label expansion on July 1 that allows Vertex’s one-time CRISPR-based therapy Casgevy to be used in children aged two and older with sickle cell disease or transfusion-dependent β thalassemia.
- Pivotal pediatric results that supported the decision showed that all eight evaluable children with sickle cell disease went 12 consecutive months without severe vaso-occlusive crises and eight of nine evaluable β thalassemia patients achieved 12-month transfusion independence.
- Casgevy is an autologous therapy made from a patient’s own blood stem cells that are edited with CRISPR/Cas9 to boost fetal hemoglobin and thereby reduce red‑cell sickling and the need for transfusions.
- The FDA completed the supplemental review in 53 days under the Commissioner’s National Priority Voucher pilot program, speeding the decision but leaving practical rollout issues unresolved.
- Widespread use will depend on scaling complex manufacturing, setting prices and coverage, and tracking longer-term safety risks such as off-target edits and engraftment failures while clinicians weigh the therapy against transplants and chronic drugs.